6533b82afe1ef96bd128ba79
RESEARCH PRODUCT
Biopharma business models in Canada.
Isidre March-chordaRosa M. Yagüe-peralessubject
PharmacologyProteomicsCanadaKnowledge managementDrug Industrybusiness.industryManagement scienceResearchComputational BiologyTimelineBusiness modelSet (abstract data type)New business developmentDrug DesignModels OrganizationalDrug DiscoveryHumansHuman resourcesbusinessBiotechnologydescription
This article provides new insights into the different strategy paths or business models currently being implemented by Canadian biopharma companies. Through a case-study methodology, seven biopharma companies pertaining to three business models were analyzed, leading to a broad set of results emerging from the following areas: activity, business model and strategy; management and human resources; and RD, technology and innovation strategy. The three business models represented were: model 1 (conventional biotech oriented to new drug development, radical innovation and search for discoveries); model 2 (development of a technology platform, usually in proteomics and bioinformatics); and model 3 (incremental innovation, with shorter and less risky development timelines).
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-08-01 | Drug discovery today |